Journal of Hematology - Supplements - Haematologica

More documents

Recommendations

Info

16 References 1. Kinsey SE. Pediatric problems. In: Barret J. and Treleaven J. Eds. The clinical practice of stem cell transplantation, Oxford: Isis Medical Media; 1998. pp.839- 48. 2. Pession A, Rondelli R, Paolucci P, et al. Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica 2000; 85:638-46. 3. Garaventa A, Porta F, Rondelli R, et al. Early deaths in children after BMT. Bone Marrow Transplantation Group of the Italian Association for Pediatric Hematology and Oncology (AIEOP) and Gruppo Italiano Trapianto di Midollo (GITMO). Bone Marrow Transplant 1992; 10:419-23. 4. Sanders JE. Growth and development after hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ Eds. Hematopoietic cell transplantation. Malden: Blackwell Science; 1999. pp. 764-75. 5. Galotto M, Berisso G, Delfino L, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999; 27:1460-6. 6. Tutschka PJ. Marrow ablation: the need for space, immune suppression, and malignant cell eradication. In: Atkinson K. Eds. Clinical bone marrow and blood stem cell transplantation. Cambridge: Cambridge University Press; 2000 pp. 13-8. 7. Buckner CD, Besinger WI. Preparative Regimens.. In: Thomas ED, Blume KG, Forman SJ eds. Hematopoietic cell transplantation. Malden: Blackwell Science; 1999 pp. 123-34. 8. Phillips GL. Conditioning regimens. In: Deeg HJ, Klingemann HG, Phillips GL, van Zant G. eds. A guide to blood and marrow transplantation. Berlin: Springer; 1999. pp. 53-67. 9. Slavin S, Nagler A, Naparstek E, et al. Immunotherapy of leukemia in conjunction with non-myeloablative conditioning: engraftment of blood stem cells and eradication of host leukemia with non-myeloablative conditioning based on Fludarabine and anti-thymocyte globulin (ATG). Blood 1996; 88:614a. 10. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-63. 11. Storb R. Nonmyeloablative preparative regimens: experimental data and clinical practice. In: Perry MC editor. American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology; 1999 pp.241-5. 12. Storb R, Yu C, McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: Thomas ED, Blume KG, Forman SJ eds. Hematopoietic cell transplantation. Malden: Blackwell Science; 1999 pp. 287-95. 13. Kapelushnik J, Or R, Aker M, et al. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant 1997; 19:96- 8. 14. O’Reilly RJ, Friedrich W, Small TN Hematopoietic cells transplantation for immunodeficiency diseases. In: Thomas ED, Blume KG, Forman SJ eds. Hematopoietic cell transplantation. Malden: Blackwell Science; 1999 pp.1154-72. 15. Lucarelli G, Clift RA. Marrow transplantation in Thalassemia. In: Thomas ED, Blume KG, Forman SJ eds. Hematopoietic cell transplantation. Malden: Blackwell Science; 1999 pp. 1137-44. 16. Deeg HJ. Rationale and indications for transplantation. In: Deeg HJ, Klingemann HG, Phillips GL, van Zant G. eds. A guide to blood and marrow transplantation. Berlin: Springer; 1999 pp. 7-14. 17. Kolb HJ. Management of relapse after hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell transplantation. Malden: Blackwell Science; 1999 pp. 929-36. 18. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocytes infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-44. 19. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versusleukemia without myeloablative therapy. Blood 1997; 89:4531-6. 20. Khouri IF, Keating M, Körbling , et al. Transplant-lite: induction of Graft-Versus-Malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24. 21. Carella AM, Lerma E, Dejana A, et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998; 83:904-9. 22. McSweeney PA, Wagner JL, Maloney DG, et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood 1998; 92:519a (Abstr. 2133). 23. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohematopoietic chimerism and graft versus lymphoma effect are achievable in adult recipients following nonmyeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet 1999; 353: 1755-9. 24. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94:3234-41. 25. Bacigalupo A. Hematopoietic stem cell transplant after reduced intensity conditioning regimen (RI- HSCT): report of a workshop of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2000; 25:803-5. 26. Bornhäuser M, Thiede C, Schuler U, et al. Dosereduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000; 26:119-25. 27. Carella AM, Champlin R, Slavin S, et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000; 25:345-50. 28. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 2000; 85:304-13. 29. Grigg A, Bardy P, Byron K, et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 1999; 23:107- 10. 30. Niederwiesar D, Wolff D, Mantovani L, et al. Hematopoietic stem cell transplant (HSCT) from HLA matched and mismatched unrelated donors using haematologica vol. 85(supplement to n. 11):November 2000
17 non-myeloablative regimen. Blood 1999; 94:581a. 31. Martino R, Sierra J. Allogeneic hematopoietic stem cell transplantation after immunosuppressive but nonmyeloablative conditioning “miniallografts” are no small matter. Haematologica 1998; 83:865-7. 32. Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25:1021-8. 33. Nagler A, Or R, Naparstek E, et al. Matched unrelated bone marrow transplantation using a non-myeloablative conditioning regimen. Blood 1998; 92: 289a. 34. Nagler A, Ackerstein A, Kapelushnik J, et al. Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 1999; 24:339-42. 35. Rao AS. Microchimerism and its role in the induction of transplantation tolerance. Cancer Res Ther Control 1998; 7:7-11. 36. Spitzer TR, McAfee S, Sackstein S, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6:309- 20. 37. Kapelushnik J, Or R, Slavin S, Nagler A. A fludarabinebased protocol for bone marrow transplantation in Fanconi’s anemia. Bone Marrow Transplant 1997; 20:1109-10. 38. Or R, Kapelushnik J, Naparstek E, et al. Second transplantation using allogeneic peripheral blood stem cells in a b-thalassemia major patient featuring stable mixed chimerism. Br J Haematol 1996; 94:285-7. 39. Aker M, Varadi G, Slavin S, et al. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi’s anemia. J Pediatr Hematol Oncol 1999; 21:237-9. 40. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000; 28:1096- 104. 41. Kapelushnik J, Mandel H, Varadi G, et al. Fludarabinebased protocol for haploidentical peripheral blood stem cell transplantation in Hurler Syndrome. J Pediat Hematol Oncol (submitted). 42. Corradini P, Bregni M, Tarella C, et al. Allografting for high-risk hematological and solid tumors: reduced intensity chemotherapy followed by reinfusion of lymphocytes engineered with thymidine kinase gene. Bone Marrow Transplant 2000; 25:396a. 43. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000; 28: 853-7. haematologica vol. 85(supplement to n. 11):November 2000
Page 1 and 2: Haematologica established in 1920 e
Page 3 and 4: haematologica Journal of Hematology
Page 5 and 6: 3 Table 1. Indications for allogene
Page 7 and 8: 5 ease-free survival for childhood
Page 9 and 10: 7 Allogeneic bone marrow transplant
Page 11 and 12: haematologica 2000; 85(supplement t
Page 13 and 14: 11 achieved. However the relapse ra
Page 15 and 16: 13 ease. This observation is confir
Page 17: 15 plant failure. The role of DLI i
Page 21 and 22: apheretic products obtained after m
Page 23 and 24: 21 Kinetics of activation of CFC in
Page 25 and 26: 23 according to the flow cytometric
Page 27 and 28: 25 mal cell activators and inhibito
Page 29 and 30: 27 reduced responsiveness to alloge
Page 31 and 32: 29 15 from activated cord versus ad
Page 33 and 34: 31 reported on the initial experien
Page 35 and 36: 33 Table 5. Timing and causes of tr
Page 37 and 38: 35 of children with storage disorde
Page 41 and 42: 39 parents wishes (the patient was
Page 45 and 46: 43 washing the cell suspension and
Page 47 and 48: 45 tive selection is usually around
Page 51 and 52: 49 chemotherapy blocks has been adm
Page 53 and 54: 51 Recently some clinical studies h
Page 55 and 56: 53 lymphoblastic leukaemia in Italy
Page 57 and 58: 55 Table 1. Summary of clinical dat
Page 59 and 60: 57 HLA-restricted cytomegalovirus (
Page 61 and 62: 59 that short-term artificial nutri
Page 63 and 64: 61 chain triglycerides in total par
Page 65 and 66: 63 1 2 3 4 5 Figure 1. Answers to t
Page 67 and 68: 65 References 1. Clarke DE, Raffin
Page 69 and 70:
67 therapy including colony-stimula
Page 71 and 72:
69 platin-thiotepa-etoposide is 34%
Page 73 and 74:
haematologica 2000; 85(supplement t
Page 75 and 76:
73 Multiple sclerosis MS is charact
Page 77 and 78:
75 Special Issues Conditioning The
Page 79 and 80:
77 ticated studies with gene-marked
Page 81 and 82:
79 treatment of poor risk systemic
Page 83 and 84:
Page 85 and 86:
83 Table 1. Rheumatologic disorders
Page 87 and 88:
85 ly in terms of steroid-sparing a
Page 89 and 90:
87 the same buffer was added to all
Page 91 and 92:
Page 93 and 94:
91 patients, 10 with a systemic for
Page 95 and 96:
I index of authors Albertini A 41 A
show all

Journal of Hematology - Supplements - Haematologica

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?